Literature DB >> 2522876

Thrombospondin in malignant and non-malignant breast tissue.

D A Pratt1, W R Miller, J Dawes.   

Abstract

Cytosols of malignant breast tissue contained significantly higher levels of thrombospondin (TSP) and von Willebrand factor (vWF) than non-malignant breast. TSP and vWF content of human breast were significantly correlated whereas there was no correlation between TSP and the platelet-specific protein beta-thromboglobulin (beta TG). Whilst TSP in pre-menopausal breast cancer was slightly lower than in post-menopausal breast cancer, it did not correlate with oestrogen receptors (ER) or progesterone receptors (PR), but was negatively correlated with tissue-type plasminogen activator (tPA), an oestradiol-inducible enzyme. Secretion of TSP by MCF-7 cells was low and refractory to hormones. High levels of TSP appeared to be associated with the centre of the tumour mass. It is suggested that activation of the endothelium may be responsible, at least in part, for the high levels of TSP found in malignant breast tissue and could be a factor in the growth and spread of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522876     DOI: 10.1016/0277-5379(89)90028-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  17 in total

1.  A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome.

Authors:  Zhi Zeng; Marina Hincapie; Sharon J Pitteri; Samir Hanash; Joost Schalkwijk; Jason M Hogan; Hong Wang; William S Hancock
Journal:  Anal Chem       Date:  2011-05-23       Impact factor: 6.986

2.  TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy.

Authors:  Huiming Zhang; Xiang Qu; Xuemei Ma; Tingting Wang; Yao Yang; Zhicheng Ge; Zhongtao Zhang; Zhigang Bai; Yinguang Gao; Zhu Yuan; Zihan Wang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-12

3.  Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin.

Authors:  P Jurasz; M W Stewart; A Radomski; F Khadour; M Duszyk; M W Radomski
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours.

Authors:  M Patey; B Delemer; G Bellon; L Martiny; M Pluot; B Haye
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

5.  Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.

Authors:  S Y Wong; A T Purdie; P Han
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

6.  Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.

Authors:  Daniel J Lindner; Yan Wu; Rebecca Haney; Barbara S Jacobs; John P Fruehauf; Ralph Tuthill; Ernest C Borden
Journal:  Matrix Biol       Date:  2012-11-30       Impact factor: 11.583

7.  Estrogen regulation of thrombospondin-1 in human breast cancer cells.

Authors:  Salman M Hyder; Yayun Liang; Jianbo Wu
Journal:  Int J Cancer       Date:  2009-09-01       Impact factor: 7.396

8.  Scatter factor binds to thrombospondin and other extracellular matrix components.

Authors:  K Lamszus; A Joseph; L Jin; Y Yao; S Chowdhury; A Fuchs; P J Polverini; I D Goldberg; E M Rosen
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

9.  Distribution of thrombospondin and integrin alpha V in DCIS, invasive ductal and lobular human breast carcinomas. Analysis by electron microscopy.

Authors:  C M Serre; P Clezardin; L Frappart; G Boivin; P D Delmas
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium.

Authors:  M L Iruela-Arispe; P Porter; P Bornstein; E H Sage
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.